BioVaxys Technology Corp. has successfully closed a private placement of unsecured convertible debentures, raising CAD 335,670 in gross proceeds to support the development of its vaccine and immunotherapy pipeline.

BioVaxys Technology Corp. has successfully completed a non-brokered private placement of unsecured convertible debentures, raising $335,670 to fund its research and development activities, particularly the progression of its malaria vaccine, VaxMite.

BioVaxys Technology Corp, a Canadian biotech company, is developing innovative vaccines and immunotherapy products to address global health challenges, including infectious diseases and cancer.

BioVaxys Technology Corp is a Canadian biotech company innovating in global health, developing novel vaccines and therapies for infectious diseases and cancer, with a focus on addressing critical health challenges.